简体中文

论著-头颈部

T3-T4N0N3期鼻咽癌同期放化疗分层疗效分析

作者:李 工 孔怡琳 詹文婷 薛晓光 郑剑霄 高 蕾 郭伟伟 邱圣红

所属单位:广东省中医院大学城医院放疗科(广东 广州 510006)

PDF

摘要

目的研究不同T分期与N分期中 采用同期放化疗治疗对鼻咽癌患者的临床 疗效。方法 选择132例鼻咽癌患者为研究 对象,均在2014年10月完成所有治疗及随 访,采用对照研究的方式将其分为两组, T分期组(60例)和N分期组(72例);均行放 化同期治疗,对两组患者的临床疗效及不 良反应进行归纳总结。结果 两组患者各 项并发症发生率无明显差异;T分期组患 者治疗总有效率为80.0%,N分期组患者 治疗总有效率为84.7%;两组患者在复发 率、转移率、复发并转移率、3年生存率 及5年生存率的比较上χ2 =7.31、10.43、 7.74、4.95、4.48,P均<0.05,差异具 有统计学意义。结论 鼻咽癌患者采用放 化同期治疗,其病情的预后和转归与N分 期和T分期具有相关性,但N分期为主导因 素,对患者行分层放疗可有助于提高临床 疗效。

Objective This paper is to study clinical efficacy of mere radiotherapy applied to treat patients with nasopharyngeal carcinoma at sub-stage T and sub-stage N. Methods One hundred and thirty two patients with nasopharyngeal carcinoma (NPC) were selected as research subjects, all of those patients completed the treatment and followup as of October, 2014, and the manner of control study was applied to divide them into two groups with 60 patients at T sub-stage group and 72 patients in N sub-stage group, patients in two groups were subject mere radiotherapy treatment, clinical efficacy and adverse effects of patients in two groups were summarized. Results There was no significant difference in the rate of complications of patients in two groups, the total effective rate of patients in T sub-stage group and N sub-stage group hit 80% and 84.7% respectively, the comparison in the recurrence rate, metastasis rate, rate of recurrence and metastasis, three-year survival rate and five-year survival rate hit χ2 =7.31, 10.43, 7.74, 10.43 and 7.74 respectively with average P<0.05, and the difference was statistically significant. Conclusion Mere radiotherapy applied on patients with nasopharyngeal carcinoma delivers efficacy, the prognosis and outcome of illness are associated with N sub-stage and T sub-stage, while the N sub-stage serves as the leading factor, and stratified radiotherapy can facilitate improving clinical efficacy of patients.

【关键词】鼻咽癌;T分期;N分期;放化同期;临床疗效

【中图分类号】R730.55

【文献标识码】A

【DOI】10.3969/j.issn.1672-5131.2015.08.006

前言

鼻咽癌在中国的发病率高,特别集中在南方,临床采用根治性放 疗具有较好疗效,不同分期的患者疗效不一,同一分期患者在不同的 亚组之间的疗效也具有显著的差异;临床对各亚型的疗效有待进一步 研究。T3T4期鼻咽癌患者的远期疗效欠佳,采用放化同期的5年内生 存率一直控制在约60%[1]。有学者提出应根据肿瘤分期进行分层放疗治 疗,制定临床鼻咽癌治疗的新指导[2]。本文对不同分期鼻咽癌患者采 用放化同期治疗的疗效进行分析归纳,取得较满意效果,现进行如下 分析。